| abstract |
The present invention provides a compound, a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof for use in a method for the treatment and / or prevention of leukemia. A compound of the following formula, a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof. Wherein X is selected from the group consisting of N—R 1 , O and S; R 1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and H; R 2 is indolyl; Selected from the group consisting of substituted indolyl, azaindolyl and substituted azaindolyl; R 3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.) [Selection figure] None |